Implementing State-of-the-Art, Reproducible & Predictive Oncology Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability
July 23-24, 2024 | Boston, MA
The Only Industry-Led Meeting Uniting Pharma and Biotech from the East Coast to Network and Discuss New Trends and Innovations in Tumor Models
In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery.
The 12th Annual Tumor Models Boston Summit is the only industry-led meeting uniting 200+ industry experts from pharma, biotech, academic KOLs and preclinical CROs to delve into the latest case studies in leveraging PDX models, genetically engineered mouse models, advanced 3D in vitro models and more. Join industry leaders developing teams in preclinical, translational, pharmacology, discovery, pharmacodynamics, toxicity and biology to optimize and implement more translatable oncology models.
Your World Class 2024 Speaker Faculty Includes:
Tamar Uziel
Scientific Director, Research Fellow; Precision Medicine Oncology, Translational Research, Lead
Abbvie
A Snapshot of What 2024 Has In-Store:
Discover how to utilize PDX models to optimize patient representation with AstraZeneca
Develop and understand the mode of action of tumor models using in vivo imaging biomarkers, with Merck
Identify potential biomarkers before evaluating in the clinic, presented by Abbvie
Use in vivo and in vitro models to effectively recapitulate the tumor stroma and fibroblasts, with Amgen
Elucidate an in vivo gene therapy approach to reprogram the patients’ immune cells to fight cancer, with exclusive insights from Sanofi
Uncover the latest advances in utilizing humanized mouse models, GEMMs, CDX, PDX & organoids to optimize IO preclinical research & improve clinical translation
Companies That Shared Insights In 2023:
Our 2024 Partners:
Other Events in the Series
